.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,025,290

« Back to Dashboard

Claims for Patent: 7,025,290

Title:Generation of therapeutic microfoam
Abstract: Improved therapeutic sclerosing microfoams are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.
Inventor(s): Osman; Tariq (London, GB), Harman; Anthony David (Checkendon, GB), Boorman; Timothy David (Frinton on Sea, GB), Flynn; Sheila Bronwen (Nr. Stevenage, GB), Wright; David Dakin Iorwerth (High Wycombe, GB)
Assignee: BTG International Limited (London, GB)
Application Number:10/300,758
Patent Claims: 1. A method for producing a microfoam suitable for use in sclerotherapy of blood vessels characterized in that it comprises passing a mixture of a physiologically acceptable blood dispersible gas and an aqueous sclerosant liquid through one or more passages having at least one cross-sectional dimension of from 0.1 to 30 .mu.m, the ratio of gas to liquid being controlled such that a microfoam is produced having a density of between 0.07 g/mL to 0.19 g/mL and has a half-life of at least 2 minutes.

2. A method as claimed in claim 1 the gas/liquid ratio in the mixture is controlled such that the density of the microfoam is 0.09 g/mL to 0.16 g/mL.

3. A method as claimed in claim 1 characterized in that at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 200 .mu.m diameter and at least 95% of these gas bubbles are no more than 280 .mu.m diameter.

4. A method as claimed in claim 1 characterized in that at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 150 .mu.m diameter and at least 95% of these gas bubbles are no more than 250 .mu.m diameter.

5. A method as claimed in claim 1 characterized in that the mixture of gas and sclerosant liquid is in the form of an aerosol, dispersion of bubbles in liquid or macrofoam.

6. A method as claimed in claim 1 characterized in that the ratio of gas to liquid used in the mixture is 1 gram sclerosant liquid to from 6.25 to 14.3 volumes of gas at standard temperature and pressure.

7. A method as claimed in claim 1 characterized in that the physiologically acceptable blood dispersible gas comprises a major proportion of carbon dioxide and/or oxygen.

8. A method as claimed in claim 1 characterized in that the aqueous sclerosant liquid is a solution of polidocanol or sodium tetradecylsulfate (STS) in an aqueous carrier.

9. A method as claimed in claim 8 characterized in that the carrier comprises a saline solution.

10. A method as claimed claim 1 characterized in that the cross-sectional dimension is diameter and the one or more passages through which the gas and liquid mixture are passed to produce the microfoam have diameter of from 5 .mu.m to 25 .mu.m.

11. A method as claimed in claim 10 characterized in that the passages are of from 10 .mu.m to 20 .mu.m diameter and are openings in a mesh or screen placed perpendicular to the direction of flow of the gas/liquid mixture.

12. A method as claimed in claim 10 characterized in that the passages are provided as multiple openings in one or more elements through which the mixture flows.

13. A method as claimed in claim 12 characterized in that the multiple openings provide a 2% to 65% open area in the one or more elements.

14. A method as claimed in claim 12 characterized in that the element comprises porous material and a number said elements are arranged sequentially such that the gas and liquid pass through the passages of each element.

15. A method as claim in claim 14 characterized in that the elements are spaced and are placed along the direction of flow of the mixture in series.

16. A method as claimed in claim 1 characterized in that the mixture of gas and liquid is passed through the same passage or passages a number of times.

17. A method as claimed in claim 1 characterized in that the gas is pressurized at 0.1 to 9 bar over atmospheric pressure.

18. A method as claimed in claim 17 characterized in that the gas is pressurized at 0.1 to 3 bar over atmospheric pressure.

19. A device for producing a microfoam suitable for use in sclerotherapy of blood vessels comprising a housing in which is sutuated a pressurisable chamber with one or more outlet orifices, a pathway by which contents of the chamber may be passed to an exterior of the housing through the one or more outlet orifices, and a mechanism by which the chamber can be pressurized such that its contents therein pass to the exterior along the pathway and through the one or more outlet orifices, said pathway to the exterior of the housing or the chamber including one or more elements defining one or more passages of cross sectional dimension 0.1 .mu.m to 30 .mu.m through which contents of the chamber are passed upon actuation of the mechanism, wherein the chamber contains an aqueous sclerosant liquid and/or a physiologically acceptable blood dispersible gas.

20. A device as claimed in claim 19 characterized in that the microfoam is of density 0.09 to 0.16 g/mL.

21. A device for producing a microfoam suitable for use in sclerotherapy of blood vessels comprising a housing in which is situated a pressurisable chamber with one or more outlet orifices, a pathway by which contents of the chamber may be passed to an exterior of the housing through the one or more outlet orifices, and a mechanism by which the chamber can be pressurized such that its contents therein pass to the exterior along the pathway and through the one or more outlet orifices, said pathway to the exterior of the housing or the chamber including one or more elements defining one or more passages of cross sectional dimension 0.1 .mu.m to 30 .mu.m through which contents of the chamber are passed upon actuation of the mechanism, wherein the elements defining the passages in the pathway or chamber are mounted on a moveable support, said support being moveable by manipulation from outside of the chamber.

22. A device as claimed in claim 21 wherein the one or more elements defining one or more passages are provided in the form of porous membranes, meshes, screens or sinters.

23. A device as claimed in claim 21 characterized in that it comprises a series of the elements defining said passages arranged in parallel with their major surfaces perpendicular to the pathway.

24. A device for delivering microfoam to a syringe from a microfoam generating device as claimed in claim 19 characterized in that it comprises an inlet conduit for engaging the outlet of the microfoam producing device in a microfoam tight fashion, the conduit being connected to and leading through a multipath valve for directing microfoam passing down the conduit, the valve being capable of being set to direct microfoam down either of first and second outlet conduits or for closing the inlet conduit, the syringe luer outlet being received by one of the first and second outlet conduits.

25. A device as claimed in claim 24 further comprising one or more elements for engaging the microfoam producing device other than by its outlet nozzle to hold it securely.

26. A device as claimed in claim 25 further comprising a base element, sufficiently stable to mount a microfoam producing device adjacent a multipath-valve said inlet being attachable to the microfoam producing device outlet conduit.

27. A device as claimed in claim 26 further comprising an activating element which operates to cause the pathway within the microfoam producing device to be opened to the inlet conduit.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc